journal
MENU ▼
Read by QxMD icon Read
search

Pharmacopsychiatry

journal
https://www.readbyqxmd.com/read/28718182/driving-under-the-influence-of-antidepressants-a-systematic-review-and-update-of-the-evidence-of-experimental-and-controlled-clinical-studies
#1
Alexander Brunnauer, Gerd Laux
Introduction This review provides an update of experimental and clinical studies on the effects of antidepressants on driving performance. Methods A systematic literature search on the PubMed database (1980-2016) was performed. Results Twenty-eight studies could be included in this review, whereas only 5 studies investigated driving performance under antidepressants in patients. Most tri- and tetracyclics have acute deleterious effects on driving performance that, except for mianserin, attenuate after subchronic use...
July 17, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28718181/erythropoietin-for-cognitive-deficits-associated-with-schizophrenia-bipolar-disorder-and-major-depression-a-systematic-review
#2
Xian-Bin Li, Wei Zheng, Yu-Ping Ning, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Chuan-Yue Wang, Yu-Tao Xiang
Introduction The purpose of this study is to systematically review the efficacy and safety of adjunctive erythropoietin (EPO) in treating cognitive deficits associated with schizophrenia, bipolar disorder, and major depression based on randomized controlled trials (RCTs). Methods Two evaluators independently and systematically searched and selected studies, extracted data, and conducted quality assessment. Results Four RCTs with 144 patients (71 in the EPO group and 73 in the placebo group) met the study entry criteria...
July 17, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28675912/influence-of-long-term-benzodiazepine-use-on-neurocognitive-skills-related-to-driving-performance-in-patient-populations-a-review
#3
Nick N J J M van der Sluiszen, Annemiek Vermeeren, Stefan Jongen, Frederick Vinckenbosch, Johannes G Ramaekers
Acute benzodiazepine intoxication produces severe impairment of neurocognitive skills related to driving. It is less clear whether such impairments also occur in patients who use benzodiazepines chronically. The current review evaluated neurocognitive skills of long-term benzodiazepine users and addressed 2 major questions: do long-term users develop tolerance for the impairing effects of benzodiazepines on neurocognitive performance, and if so, does tolerance warrant a change in driver fitness classification systems that currently deem users of benzodiazepines unfit to drive? Neurocognitive impairments were reported in patients who on average used benzodiazepines for 5-15 years...
July 4, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28675911/patients-knowledge-about-prescribed-antipsychotics-and-medication-adherence-in-schizophrenia-a-cross-sectional-survey
#4
Nobuhiro Nagai, Hideaki Tani, Takefumi Suzuki, Saeko Ikai, Philip Gerretsen, Masaru Mimura, Hiroyuki Uchida
Introduction Data on the knowledge about antipsychotic medications prescribed in patients with schizophrenia are very limited. Moreover, it remains unclear how patients' knowledge about prescribed antipsychotics affects medication adherence. Methods ighty-one Japanese outpatients with schizophrenia according to the International Classification of Diseases, 10th edition, were included. Patients' knowledge of the primary antipsychotics prescribed to them in terms of therapeutic effects, type, and implicated neurotransmitters was assessed with a multiple-choice questionnaire developed for this study...
July 4, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28672405/driving-performance-of-depressed-patients-who-are-untreated-or-receive-long-term-antidepressant-ssri-snri-treatment
#5
Nick N J J M van der Sluiszen, Marleen Wingen, Annemiek Vermeeren, Frederick Vinckenbosch, Stefan Jongen, Johannes G Ramaekers
Introduction Depression is a mental disorder likely to affect everyday functions. The present study aimed to assess actual driving performance of depressed patients who were without specific antidepressant treatment or received long-term antidepressant treatment. Methods A standardized on-the-road driving test was used to assess standard deviation of lateral position (SDLP) in 3 patient groups receiving either no antidepressant treatment (with or without benzodiazepine medication) or treatment with selective serotonin/noradrenalin reuptake inhibitors for a period of 6-52 weeks...
July 3, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28641333/validation-of-brain-angiotensin-system-blockade-as-a-novel-drug-target-in-pharmacological-treatment-of-neuropsychiatric-disorders
#6
Dominik Wincewicz, Jan J Braszko
Retreat in psychiatric drug development results in innovative medication decline that might be at least partially overcome by adjunct therapy. New evidence from clinical studies has shown a possible role for brain Renin-Angiotensin System (RAS) in both affective and psychotic disorders. Simultaneously, rapidly accumulating data from basic studies indicate effectiveness of central RAS blockade in much broader range of neuropsychiatric disease. Recent findings implicate brain RAS, especially Angiotensin II (Ang II), in neural pathophysiology of mental disorders through neuroendocrine modulation and effects on neurotransmitter release, mostly noradrenaline, acetylcholine and dopamine...
June 22, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28641332/executive-dysfunctions-predict-self-restricted-driving-habits-in-elderly-people-with-or-without-alzheimer-s-dementia
#7
Ilsemarie Kurzthaler, Georg Kemmler, Michaela Defrancesco, Bernadette Moser, Wolfgang W Fleischhacker, Elisabeth M Weiss
Introduction The purpose of this study was to elucidate the impact of specific cognitive functions on self-restricted driving habits in healthy elderly drivers and patients suffering from mild cognitive impairment (MCI) and Alzheimer's dementia (AD). Method Our study population included 35 cognitively healthy controls, 10 MCI patients, and 16 patients with AD. All participants completed a neuropsychological examination and a self-reported questionnaire assessing driving habits and patterns. Results In challenging driving conditions, patients with MCI or AD showed significantly more driving self-restriction than healthy subjects (effect size d=1...
June 22, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28571077/a-systematic-review-of-mechanisms-of-change-in-body-oriented-yoga-in-major-depressive-disorders
#8
K Meister, G Juckel
Introduction Despite empirical evidence for the efficacy of body-oriented yoga as add-on treatment for major depressive disorder (MDD), the specific mechanisms by which yoga leads to therapeutic changes remain unclear. By means of a systematic review, we evaluate how the field is progressing in its empirical investigation of mechanisms of change in yoga for MDD. Methods To identify relevant studies, a systematic search was conducted. Results The search produced 441 articles, of which 5 were included, that empirically examined 2 psychological mechanisms (mindfulness, rumination) and 3 biological mechanisms (vagal control, heart rate variability [HRV], brain-derived neurotrophic factor [BDNF], cortisol)...
June 1, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28561203/relationship-between-daily-dose-serum-concentration-and-clinical-response-to-quetiapine-in-children-and-adolescents-with-psychotic-and-mood-disorders
#9
Laura Albantakis, Karin Egberts, Rainer Burger, Christine Kulpok, Claudia Mehler-Wex, Regina Taurines, Stefan Unterecker, Christoph Wewetzer, Marcel Romanos, Manfred Gerlach
Introduction In child and adolescent psychiatry, therapeutic drug monitoring (TDM) is strongly recommended. However, therapeutic ranges (TR) are defined only for adults. The objectives of this naturalistic study were to assess the relationships between serum quetiapine concentration, daily dose, and clinical outcomes as well as the determinants of pharmacokinetic variability. Furthermore, it was elucidated whether the recommended TR for adult patients with psychotic disorders is valid for children and adolescents...
May 23, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28521367/driving-problems-in-the-elderly-and-cognitively-impaired
#10
Robert Haussmann, Maria Buthut, Markus Donix
Driving ability in the elderly and cognitively impaired is of growing demographic relevance. Driving represents a complex task for which multiple central resources are needed. In mild cognitive impairment and dementia, we need to closely monitor driving ability, as it gets irrecoverably lost in the course of the disease. In normal aging, people are often able to self-regulate driving behavior with respect to their medical conditions. Some studies demonstrated that older drivers perform well compared with younger drivers...
May 18, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28482360/new-onset-of-suicidal-impulses-following-abrupt-cessation-of-valproate
#11
Johannes Ladwig, Dorothea Andreae, Renate Grohmann, Sermin Toto, Stefan Kropp, Stefan Bleich
No abstract text is available yet for this article.
May 8, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28482359/author%C3%A2-s-reply-to-the-letter-to-the-editor-by-fountoulakis
#12
Shahin Akhondzadeh, Alireza Ghajar
No abstract text is available yet for this article.
May 8, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28511206/antipsychotic-treatment-of-22q11-2-deletion-syndrome-related-psychoses
#13
Elias Angelopoulos, Christos Theleritis, Marina Economou, Korina Georgatou, Charalambos C Papageorgiou, Eleftheria Tsaltas
In the recent study by Verhoeven and Egger, 2015 and the recent letter to the editor by Boot et al. 2015 an emphasis is given to the best possible pharmacological treatment of 22q11-2 Deletion-Syndrome related psychoses. We would like to present the case of a 23-year old Cypriot patient with 22q11.2 deletion syndrome who fulfilled criteria for treatment resistant schizophrenia (TRS). He was sequentially treated with aripiprazole, risperidone, olanzapine, haloperidol and a combination treatment with olanzapine and haloperidol...
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28505669/add-on-antidepressants-in-the-naturalistic-treatment-of-schizophrenia-spectrum-disorder-when-who-and-how
#14
Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Gerd Laux, Herbert Pfeiffer, Dieter Naber, Lutz G Schmidt, Wolfgang Gaebel, Joachim Klosterkötter, Isabella Heuser, Wolfgang Maier, Matthias R Lemke, Eckart Rüther, Stefan Klingberg, Markus Gastpar, Ilja Spellmann, Richard Musil, Hans-Jürgen Möller, Michael Riedel
The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models...
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28346959/mirtazapine-induces-nightmares-in-depressed-patients
#15
Jens-Armin Buschkamp, Corinna Frohn, Georg Juckel
No abstract text is available yet for this article.
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/27701683/crocus-sativus-l-versus-citalopram-in-the-treatment-of-major-depressive-disorder-with-anxious-distress-a-double-blind-controlled-clinical-trial
#16
A Ghajar, S M Neishabouri, N Velayati, L Jahangard, N Matinnia, M Haghighi, A Ghaleiha, M Afarideh, S Salimi, A Meysamie, S Akhondzadeh
Introduction: Saffron (Crocus sativus L.) has demonstrated antidepressant effects in clinical studies and extensive anxiolytic effects in experimental animal models. Methods: 66 patients with major depressive disorder accompanied by anxious distress were randomly assigned to receive either saffron (30 mg/day) or citalopram (40 mg/day) for 6 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were used to assess treatment effect during the trial. Results: 60 participants finished the study...
July 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28445899/evidence-based-guidelines-for-the-pharmacologic-management-of-methamphetamine-dependence-relapse-prevention-chronic-methamphetamine-related-and-comorbid-psychiatric-disorders-in-post-acute-settings
#17
Roland Härtel-Petri, Anne Krampe-Scheidler, Wolf-Dietrich Braunwarth, Ursula Havemann-Reinecke, Peter Jeschke, Winfried Looser, Stephan Mühlig, Ingo Schäfer, Norbert Scherbaum, Lydia Bothe, Corinna Schaefer, Willem Hamdorf
The increasing abuse of the street drug crystal meth (methamphetamine) in many countries worldwide has resulted in a growing demand to treat patients who have acquired a methamphetamine-related disorder. The results of a systematic literature search which led to the consensus-based recommendations by the Working Group of the German Agency for Quality in Medicine (Ärztliches Zentrum für Qualität in der Medizin - ÄZQ) are presented. Pharmacological treatments were reviewed in 58 out of the 103 publications included...
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28445898/dramatic-changes-over-time-of-methamphetamine-intake-in-a-german-hiv-positive-sample-of-men-who-have-sex-with-men-msm
#18
Henrike Dirks, Stefan Esser, Norbert Brockmeyer, Udo Bonnet, Fabrizio Schifano, Norbert Scherbaum
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28444659/new-psychoactive-substances-nps-a-challenge-for-the-addiction-treatment-services
#19
Norbert Scherbaum, F Schifano, Udo Bonnet
Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and toxicology of most NPS are hardly known, they are being offered, especially online, as "bath salts," as "incense mixtures," or under other misleading labels...
May 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28437807/when-the-evidence-is-not-enough-commentary-on-h%C3%A3-rtel-petri-et-al
#20
R McKetin, S Allsop
No abstract text is available yet for this article.
May 2017: Pharmacopsychiatry
journal
journal
28729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"